Header Logo

Connection

HASHEM EL-SERAG to Liver Cirrhosis

Back to Details
This is a "connection" page, showing publications HASHEM EL-SERAG has written about Liver Cirrhosis.
HASHEM EL-SERAG
Connection Strength
14.618
Liver Cirrhosis
  1. Risk of Hepatocellular Cancer in U.S. Patients With Compensated Cirrhosis Treated With Direct-Acting Antivirals Versus Interferon. Aliment Pharmacol Ther. 2025 Apr; 61(7):1226-1237.
    View in: PubMed
    Score: 0.587
  2. Serum levels of total bile acids are associated with an increased risk of HCC in patients with cirrhosis. Hepatol Commun. 2024 Nov 01; 8(11).
    View in: PubMed
    Score: 0.574
  3. PNPLA3, Obesity, and Heavy Alcohol Use in Cirrhosis Patients May Exert a Synergistic Increase Hepatocellular Carcinoma Risk. Clin Gastroenterol Hepatol. 2024 Sep; 22(9):1858-1866.e4.
    View in: PubMed
    Score: 0.557
  4. An Electronic Health Record Model for Predicting Risk of Hepatic Fibrosis in Primary Care Patients. Dig Dis Sci. 2024 Jul; 69(7):2430-2436.
    View in: PubMed
    Score: 0.556
  5. Risk Factors for Cirrhosis in Contemporary Hepatology Practices-Findings From the Texas Hepatocellular Carcinoma Consortium Cohort. Gastroenterology. 2020 07; 159(1):376-377.
    View in: PubMed
    Score: 0.419
  6. Effect of Metabolic Traits on the Risk of Cirrhosis and Hepatocellular Cancer in Nonalcoholic Fatty Liver Disease. Hepatology. 2020 03; 71(3):808-819.
    View in: PubMed
    Score: 0.416
  7. Design of the Texas Hepatocellular Carcinoma Consortium Cohort Study. Am J Gastroenterol. 2019 03; 114(3):530-532.
    View in: PubMed
    Score: 0.389
  8. Validation of the Hepatocellular Carcinoma Early Detection Screening (HES) Algorithm in a Cohort of Veterans With Cirrhosis. Clin Gastroenterol Hepatol. 2019 08; 17(9):1886-1893.e5.
    View in: PubMed
    Score: 0.383
  9. Ancestry and Risk of Hepatic Fibrosis and Inflammation in Patients With HCV Infection. Clin Gastroenterol Hepatol. 2019 08; 17(9):1912-1914.
    View in: PubMed
    Score: 0.379
  10. Risk of Hepatocellular Cancer in Patients With Non-Alcoholic Fatty Liver Disease. Gastroenterology. 2018 12; 155(6):1828-1837.e2.
    View in: PubMed
    Score: 0.375
  11. Risk of Hepatocellular Cancer in HCV Patients Treated With Direct-Acting Antiviral Agents. Gastroenterology. 2017 10; 153(4):996-1005.e1.
    View in: PubMed
    Score: 0.346
  12. Trends in 30-Day and 1-Year Mortality Among Patients Hospitalized With Cirrhosis From 2004 to 2013. Am J Gastroenterol. 2017 Aug; 112(8):1287-1297.
    View in: PubMed
    Score: 0.345
  13. ?Ongoing alcohol consumptions counteracts the benefits of sustained virological response in patients with well compensated hepatitis C cirrhosis: an observational study. Ann Hepatol. 2017 Jan-Feb 2017; 16(1):16-20.
    View in: PubMed
    Score: 0.335
  14. Early outpatient follow-up and 30-day outcomes in patients hospitalized with cirrhosis. Hepatology. 2016 08; 64(2):569-81.
    View in: PubMed
    Score: 0.319
  15. The Updated Model: An Adjusted Serum Alpha-Fetoprotein-Based Algorithm for Hepatocellular Carcinoma Detection With Hepatitis C Virus-Related Cirrhosis. Gastroenterology. 2015 Dec; 149(7):1986-7.
    View in: PubMed
    Score: 0.308
  16. Coffee and Caffeine Are Associated With Decreased Risk of Advanced Hepatic Fibrosis Among Patients With Hepatitis C. Clin Gastroenterol Hepatol. 2015 Aug; 13(8):1521-31.e3.
    View in: PubMed
    Score: 0.295
  17. Racial differences in the progression to cirrhosis and hepatocellular carcinoma in HCV-infected veterans. Am J Gastroenterol. 2014 Sep; 109(9):1427-35.
    View in: PubMed
    Score: 0.283
  18. HCV genotype 3 is associated with an increased risk of cirrhosis and hepatocellular cancer in a national sample of U.S. Veterans with HCV. Hepatology. 2014 Jul; 60(1):98-105.
    View in: PubMed
    Score: 0.279
  19. A new laboratory-based algorithm to predict development of hepatocellular carcinoma in patients with hepatitis C and cirrhosis. Gastroenterology. 2014 May; 146(5):1249-55.e1.
    View in: PubMed
    Score: 0.273
  20. Many patients with interleukin 28B genotypes associated with response to therapy are ineligible for treatment because of comorbidities. Clin Gastroenterol Hepatol. 2014 Feb; 12(2):327-333.e1.
    View in: PubMed
    Score: 0.265
  21. Dietary fructose intake and severity of liver disease in hepatitis C virus-infected patients. J Clin Gastroenterol. 2013 Jul; 47(6):545-52.
    View in: PubMed
    Score: 0.262
  22. The association between serological and dietary vitamin D levels and hepatitis C-related liver disease risk differs in African American and white males. Aliment Pharmacol Ther. 2013 Jul; 38(1):28-37.
    View in: PubMed
    Score: 0.261
  23. a-Fetoprotein in hepatocellular carcinoma surveillance: mend it but do not end it. Clin Gastroenterol Hepatol. 2013 Apr; 11(4):441-3.
    View in: PubMed
    Score: 0.255
  24. The quality of care provided to patients with cirrhosis and ascites in the Department of Veterans Affairs. Gastroenterology. 2012 Jul; 143(1):70-7.
    View in: PubMed
    Score: 0.241
  25. Higher serum testosterone is associated with increased risk of advanced hepatitis C-related liver disease in males. Hepatology. 2012 Mar; 55(3):759-68.
    View in: PubMed
    Score: 0.236
  26. Use of surveillance for hepatocellular carcinoma among patients with cirrhosis in the United States. Hepatology. 2010 Jul; 52(1):132-41.
    View in: PubMed
    Score: 0.213
  27. The utility of evaluating low serum albumin gradient ascites in patients with cirrhosis. Am J Gastroenterol. 2009 Jun; 104(6):1401-5.
    View in: PubMed
    Score: 0.196
  28. Management of the single liver nodule in a cirrhotic patient: a decision analysis model. J Clin Gastroenterol. 2005 Feb; 39(2):152-9.
    View in: PubMed
    Score: 0.147
  29. The effect of HIV coinfection on the risk of cirrhosis and hepatocellular carcinoma in U.S. veterans with hepatitis C. Am J Gastroenterol. 2005 Jan; 100(1):56-63.
    View in: PubMed
    Score: 0.146
  30. Cirrhosis and hepatocellular carcinoma in HIV-infected veterans with and without the hepatitis C virus: a cohort study, 1992-2001. Arch Intern Med. 2004 Nov 22; 164(21):2349-54.
    View in: PubMed
    Score: 0.145
  31. Phase 3 Validation of PAaM for Hepatocellular Carcinoma Risk Stratification in Cirrhosis. Gastroenterology. 2025 Mar; 168(3):556-567.e7.
    View in: PubMed
    Score: 0.144
  32. GLP-1 Receptor Agonists and Risk for Cirrhosis and Related Complications in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease. JAMA Intern Med. 2024 Nov 01; 184(11):1314-1323.
    View in: PubMed
    Score: 0.144
  33. HES V2.0 outperforms GALAD for detection of HCC: A phase 3 biomarker study in the United States. Hepatology. 2025 Feb 01; 81(2):465-475.
    View in: PubMed
    Score: 0.140
  34. The risk of end stage liver disease and hepatocellular carcinoma among persons infected with hepatitis C virus: publication bias? Am J Gastroenterol. 2003 Nov; 98(11):2535-42.
    View in: PubMed
    Score: 0.134
  35. Bioimpedance analysis predicts the etiology of cirrhosis in a prospective cohort study. Hepatol Commun. 2023 10 01; 7(10).
    View in: PubMed
    Score: 0.133
  36. Risk Stratification Model for Hepatocellular Cancer in Patients With Cirrhosis. Clin Gastroenterol Hepatol. 2023 12; 21(13):3296-3304.e3.
    View in: PubMed
    Score: 0.130
  37. Prevention of Hepatocellular Carcinoma (HCC). White Paper of the Texas Collaborative Center for Hepatocellular Cancer (TeCH) Multi-stakeholder Conference. Clin Gastroenterol Hepatol. 2023 08; 21(9):2183-2192.
    View in: PubMed
    Score: 0.129
  38. Risk stratification for hepatocellular cancer among patients with cirrhosis using a hepatic fat polygenic risk score. PLoS One. 2023; 18(2):e0282309.
    View in: PubMed
    Score: 0.128
  39. Risk factors for HCC in contemporary cohorts of patients with cirrhosis. Hepatology. 2023 03 01; 77(3):997-1005.
    View in: PubMed
    Score: 0.128
  40. Current Challenges and Future Direction in Surveillance for Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease. Semin Liver Dis. 2023 02; 43(1):89-99.
    View in: PubMed
    Score: 0.125
  41. Surveillance for hepatocellular carcinoma: does it work? Am J Gastroenterol. 2002 Oct; 97(10):2676-7.
    View in: PubMed
    Score: 0.125
  42. Admixture Mapping in African Americans Identifies New Risk Loci for HCV-Related Cirrhosis. Clin Gastroenterol Hepatol. 2023 04; 21(4):1023-1030.e39.
    View in: PubMed
    Score: 0.122
  43. GALAD demonstrates high sensitivity for HCC surveillance in a cohort of patients with cirrhosis. Hepatology. 2022 03; 75(3):541-549.
    View in: PubMed
    Score: 0.118
  44. Preparing for the NASH epidemic: A call to action. Metabolism. 2021 09; 122:154822.
    View in: PubMed
    Score: 0.115
  45. Risk factors for the development of renal dysfunction in hospitalized patients with cirrhosis. Am J Gastroenterol. 2001 Jul; 96(7):2206-10.
    View in: PubMed
    Score: 0.114
  46. A Novel Biomarker Panel for the Early Detection and Risk Assessment of Hepatocellular Carcinoma in Patients with Cirrhosis. Cancer Prev Res (Phila). 2021 06; 14(6):667-674.
    View in: PubMed
    Score: 0.112
  47. Development, Validation, and Evaluation of a Simple Machine Learning Model to Predict Cirrhosis Mortality. JAMA Netw Open. 2020 11 02; 3(11):e2023780.
    View in: PubMed
    Score: 0.109
  48. Risk of Cirrhosis and Hepatocellular Cancer in Patients With NAFLD and Normal Liver Enzymes. Hepatology. 2020 10; 72(4):1242-1252.
    View in: PubMed
    Score: 0.108
  49. External Validation of Four Point-of-Care Noninvasive Scores for Predicting Advanced Hepatic Fibrosis in a Predominantly Hispanic NAFLD Population. Dig Dis Sci. 2021 07; 66(7):2387-2393.
    View in: PubMed
    Score: 0.107
  50. Validation of the Updated Hepatocellular Carcinoma Early Detection Screening Algorithm in a Community-Based Cohort of Patients With Cirrhosis of Multiple Etiologies. Clin Gastroenterol Hepatol. 2021 07; 19(7):1443-1450.e6.
    View in: PubMed
    Score: 0.107
  51. Model for end-stage liver disease-sodium underestimates 90-day mortality risk in patients with acute-on-chronic liver failure. J Hepatol. 2020 12; 73(6):1425-1433.
    View in: PubMed
    Score: 0.106
  52. Risk Trajectories for Readmission and Death After Cirrhosis-Related Hospitalization. Dig Dis Sci. 2019 06; 64(6):1470-1477.
    View in: PubMed
    Score: 0.096
  53. Implementation of a Population-Based Cirrhosis Identification and Management System. Clin Gastroenterol Hepatol. 2018 08; 16(8):1182-1186.e2.
    View in: PubMed
    Score: 0.092
  54. Hepatocellular carcinoma screening is associated with survival benefit in silico but needs confirmation in an in vivo analysis. Hepatology. 2018 07; 68(1):7-9.
    View in: PubMed
    Score: 0.092
  55. Editorial: NAFLD-related hepatocellular carcinoma - increasing or not? With or without cirrhosis? Aliment Pharmacol Ther. 2018 02; 47(3):437-438.
    View in: PubMed
    Score: 0.090
  56. Positive Predictive Value of International Classification of Diseases, 10th Revision, Codes for Cirrhosis and Its Related Complications. Clin Gastroenterol Hepatol. 2018 10; 16(10):1677-1678.
    View in: PubMed
    Score: 0.090
  57. Evaluating screening approaches for hepatocellular carcinoma in a cohort of HCV related cirrhosis patients from the Veteran's Affairs Health Care System. BMC Med Res Methodol. 2018 01 04; 18(1):1.
    View in: PubMed
    Score: 0.090
  58. Barriers to hepatitis C treatment in the era of direct-acting anti-viral agents. Aliment Pharmacol Ther. 2017 11; 46(10):992-1000.
    View in: PubMed
    Score: 0.088
  59. Hepatocellular carcinoma surveillance: The road ahead. Hepatology. 2017 03; 65(3):771-773.
    View in: PubMed
    Score: 0.084
  60. Risk and Predictors of Variceal Bleeding in Cirrhosis Patients Receiving Primary Prophylaxis With Non-Selective Beta-Blockers. Am J Gastroenterol. 2016 12; 111(12):1778-1787.
    View in: PubMed
    Score: 0.082
  61. Role of Non-hepatic Medical Comorbidity and Functional Limitations in Predicting Mortality in Patients with HCV. Dig Dis Sci. 2017 01; 62(1):76-83.
    View in: PubMed
    Score: 0.082
  62. Effectiveness of surveillance for hepatocellular carcinoma in clinical practice: A United States cohort. J Hepatol. 2016 12; 65(6):1148-1154.
    View in: PubMed
    Score: 0.081
  63. Epidemiology and outcomes of hepatitis C infection in elderly US Veterans. J Viral Hepat. 2016 09; 23(9):687-96.
    View in: PubMed
    Score: 0.079
  64. Cirrhosis is under-recognised in patients subsequently diagnosed with hepatocellular cancer. Aliment Pharmacol Ther. 2016 Mar; 43(5):621-30.
    View in: PubMed
    Score: 0.078
  65. Clinical outcomes of hepatitis B virus coinfection in a United States cohort of hepatitis C virus-infected patients. Hepatology. 2014 Dec; 60(6):1871-8.
    View in: PubMed
    Score: 0.072
  66. The quality of care provided to patients with varices in the department of Veterans Affairs. Am J Gastroenterol. 2014 Jul; 109(7):934-40.
    View in: PubMed
    Score: 0.070
  67. WNT signaling pathway gene polymorphisms and risk of hepatic fibrosis and inflammation in HCV-infected patients. PLoS One. 2013; 8(12):e84407.
    View in: PubMed
    Score: 0.068
  68. Genetic variation in the PNPLA3 gene and hepatocellular carcinoma in USA: risk and prognosis prediction. Mol Carcinog. 2013 Nov; 52 Suppl 1:E139-47.
    View in: PubMed
    Score: 0.065
  69. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology. 2012 May; 142(6):1264-1273.e1.
    View in: PubMed
    Score: 0.061
  70. Effectiveness of AFP and ultrasound tests on hepatocellular carcinoma mortality in HCV-infected patients in the USA. Gut. 2011 Jul; 60(7):992-7.
    View in: PubMed
    Score: 0.055
  71. Utilization of surveillance for hepatocellular carcinoma among hepatitis C virus-infected veterans in the United States. Ann Intern Med. 2011 Jan 18; 154(2):85-93.
    View in: PubMed
    Score: 0.055
  72. Increasing prevalence of HCC and cirrhosis in patients with chronic hepatitis C virus infection. Gastroenterology. 2011 Apr; 140(4):1182-1188.e1.
    View in: PubMed
    Score: 0.055
  73. Prevalence and challenges of liver diseases in patients with chronic hepatitis C virus infection. Clin Gastroenterol Hepatol. 2010 Nov; 8(11):924-33; quiz e117.
    View in: PubMed
    Score: 0.054
  74. The changing pattern of epidemiology in hepatocellular carcinoma. Dig Liver Dis. 2010 Jul; 42 Suppl 3:S206-14.
    View in: PubMed
    Score: 0.053
  75. An explicit quality indicator set for measurement of quality of care in patients with cirrhosis. Clin Gastroenterol Hepatol. 2010 Aug; 8(8):709-17.
    View in: PubMed
    Score: 0.052
  76. The validity of viral hepatitis and chronic liver disease diagnoses in Veterans Affairs administrative databases. Aliment Pharmacol Ther. 2008 Feb 01; 27(3):274-82.
    View in: PubMed
    Score: 0.044
  77. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 2007 Jun; 132(7):2557-76.
    View in: PubMed
    Score: 0.043
  78. Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: a hospital-based case-control study. Am J Gastroenterol. 2007 May; 102(5):1016-21.
    View in: PubMed
    Score: 0.042
  79. Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology. 2004 Feb; 126(2):460-8.
    View in: PubMed
    Score: 0.034
  80. Serum ferritin level predicts advanced hepatic fibrosis among U.S. patients with phenotypic hemochromatosis. Ann Intern Med. 2003 Apr 15; 138(8):627-33.
    View in: PubMed
    Score: 0.032
  81. Longitudinal changes in fibrosis markers are associated with risk of cirrhosis and hepatocellular carcinoma in non-alcoholic fatty liver disease. J Hepatol. 2023 03; 78(3):493-500.
    View in: PubMed
    Score: 0.031
  82. Synergistic Associations of PNPLA3 I148M Variant, Alcohol Intake, and Obesity With Risk of Cirrhosis, Hepatocellular Carcinoma, and Mortality. JAMA Netw Open. 2022 10 03; 5(10):e2234221.
    View in: PubMed
    Score: 0.031
  83. Longitudinal Associations of Risk Factors and Hepatocellular Carcinoma in Patients With Cured Hepatitis C Virus Infection. Am J Gastroenterol. 2022 11 01; 117(11):1834-1844.
    View in: PubMed
    Score: 0.031
  84. Contemporary Changes in Etiology for Hepatocellular Carcinoma in Liver Transplantation. Clin Gastroenterol Hepatol. 2023 08; 21(9):2410-2412.e1.
    View in: PubMed
    Score: 0.031
  85. Epidemiology of hepatocellular carcinoma. Clin Liver Dis. 2001 Feb; 5(1):87-107, vi.
    View in: PubMed
    Score: 0.028
  86. Factors Associated With Delay of Diagnosis of Hepatocellular Carcinoma in Patients With Cirrhosis. Clin Gastroenterol Hepatol. 2021 08; 19(8):1679-1687.
    View in: PubMed
    Score: 0.027
  87. Women Have a Lower Risk of Nonalcoholic Fatty Liver Disease but a Higher Risk of Progression vs Men: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2021 01; 19(1):61-71.e15.
    View in: PubMed
    Score: 0.026
  88. Prevalence and short-term mortality of acute-on-chronic liver failure: A national cohort study from the USA. J Hepatol. 2019 04; 70(4):639-647.
    View in: PubMed
    Score: 0.024
  89. Hepatitis C virus-related complications are increasing in women veterans: A national cohort study. J Viral Hepat. 2017 11; 24(11):955-965.
    View in: PubMed
    Score: 0.022
  90. Hepatocellular carcinoma in the absence of cirrhosis in patients with chronic hepatitis B virus infection. J Hepatol. 2017 02; 66(2):355-362.
    View in: PubMed
    Score: 0.021
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.